The cost-effectiveness of palivizumab for respiratory...

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis*

Lanctôt, Krista L., Masoud, Shababa T., Paes, Bosco A., Tarride, Jean-Eric, Chiu, Aaron, Hui, Charles, Francis, Philip L., Oh, Paul I.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
24
Language:
english
Journal:
Current Medical Research and Opinion
DOI:
10.1185/03007990802484234
Date:
November, 2008
File:
PDF, 497 KB
english, 2008
Conversion to is in progress
Conversion to is failed